Intravenous artesunate versus intravenous quinine in the treatment of severe falciparum malaria: a retrospective evaluation from a UK centre

References

• Health Protection Agency. Health Prot. Rep. 2011;5:17–28. Available from: http://www.hpa.org.uk/hpr/archives/2011/hpr1711.pdf (accessed 28/03/2012).
   Google Scholar
• Phillips A, Bassett P, Zeki S, Newman S, Pasvol G. Risk factors for severe disease in adults with falciparum malaria. Clin Infect Dis. 2009;48(7):871–8.
   Web of Science ®Google Scholar
• Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg. 2000;94(Suppl 1):S1–90.
   Google Scholar
• Lalloo DG, Shingadia D, Pasvol G, Chiodini PL, Whitty CJ, Beeching NJ, et al.. UK malaria treatment guidelines. J Infect. 2007;54(2):111–21.
   Web of Science ®Google Scholar
• British Infection Society. Malaria — Algorithm for Initial Assessment and Management in Adults. Princes Risborough: BIS; 2007. Available from: http://www.britishinfection.org/drupal/sites/default/files/MalariaAlgorithm07.pdf (accessed 28/03/2012).
   Google Scholar
• Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. Trans R Soc Trop Med Hyg. 1990;84(Suppl 2):1–65.
   Google Scholar
• Day N, Dondorp AM. The management of patients with severe malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):29–35.
   Web of Science ®Google Scholar
• White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, Krishna S, et al.. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med. 1983;309(2):61–6.
   Web of Science ®Google Scholar
• Bonington A, Davidson RN, Winstanley PA, Pasvol G. Fatal quinine cardiotoxicity in the treatment of falciparum malaria. Trans R Soc Trop Med Hyg. 1996;90(3):305–7.
   Web of Science ®Google Scholar
• White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7(8):549–58.
   Web of Science ®Google Scholar
• Cumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv Pharmacol. 1997;37:253–97.
   PubMedGoogle Scholar
• Wu Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist’s view. Acc Chem Res. 2002;35(5):255–9.
   Web of Science ®Google Scholar
• Li W, Mo W, Shen D, Sun L, Wang J, Lu S, et al.. Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet. 2005;1(3):e36.
   Google Scholar
• ter Kuile F, White NJ, Holloway P, Pasvol G, Krishna S. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol. 1993;76(1):85–95.
   Web of Science ®Google Scholar
• Hess KM, Goad JA, Arguin PM. Intravenous artesunate for the treatment of severe malaria. Ann Pharmacother. 2010;44(7–8):1250–8.
   Web of Science ®Google Scholar
• Newton PN, Barnes KI, Smith PJ, Evans AC, Chierakul W, Ruangveerayuth R, et al.. The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. Eur J Clin Pharmacol. 2006;62(12):1003–9.
   Web of Science ®Google Scholar
• Jones KL, Donegan S, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2007;(4):CD005967.
   Google Scholar
• Krudsood S, Wilairatana P, Vannaphan S, Treeprasertsuk S, Silachamroon U, Phomrattanaprapin W, et al.. Clinical experience with intravenous quinine, intramuscular artemether and intravenous artesunate for the treatment of severe malaria in Thailand. Southeast Asian J Trop Med Public Health. 2003;34(1):54–61.
   Google Scholar
• Maude RJ, Plewes K, Faiz MA, Hanson J, Charunwatthana P, Lee SJ, et al.. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? Am J Trop Med Hyg. 2009;80:126–32.
   PubMed Web of Science ®Google Scholar
• Newton PN, Angus BJ, Chierakul W, Dondorp A, Ruangveerayuth R, Silamut K, et al.. Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin Infect Dis. 2003;37(1):7–16.
   Web of Science ®Google Scholar
• Dondorp A, Nosten F, Stepniewska K, Day N, White N; South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366(9487):717–25.
   Web of Science ®Google Scholar
• Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al.. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376(9753):1647–57.
   PubMed Web of Science ®Google Scholar
• Lubell Y, Yeung S, Dondorp AM, Day NP, Nosten F, Tjitra E, et al.. Cost-effectiveness of artesunate for the treatment of severe malaria. Trop Med Int Health. 2009;14(3):332–7.
   Web of Science ®Google Scholar
• World Health Organization. Guidelines for the treatment of malaria 2nd edition. Geneva: WHO; 2010. Available from: http://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf (accessed 28/03/2012).
   Google Scholar
• World Health Organization. Guidelines for the treatment of malaria 2nd edition — Rev. 1. Geneva: WHO; 2011. Available from: http://www.who.int/malaria/publications/atoz/mal_treatchild_revised.pdf (accessed 28/03/2012).
   Google Scholar
• Centers for Disease Control and Prevention. Artesunate is available to treat severe malaria in the United States, 8 February 2010. Available from: http://www.cdc.gov/malaria/diagnosis_treatment/artesunate.html (accessed 28/03/2012).
   Google Scholar
• Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, et al.. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis. 2011;17(5):771–7.
   Web of Science ®Google Scholar
• Bartoloni A, Tomasoni L, Bartalesi F, Galli L, Sani S, Veloci S, et al.. Combined intravenous treatment with artesunate and quinine for severe malaria in Italy. Am J Trop Med Hyg. 2010;83(2):274–6.
   Web of Science ®Google Scholar
• Mørch K, Strand Ø, Dunlop O, Berg A, Langeland N, Leiva RA, et al.. Severe malaria and artesunate treatment, Norway. Emerg Infect Dis. 2008;14(11):1816–8.
   Web of Science ®Google Scholar
• Lesi AF, Meremikwu MM. High first dose quinine regimen for treating severe malaria. Cochrane Database Syst Rev. 2004;(3):CD003341.
   Google Scholar
• Tariq M, et al.. Efficacy and safety of quinine loading dose in patients with severe falciparum malaria at a tertiary care hospital in Pakistan. J Pak Med Assoc. 2011;61(1):27–31.
   Web of Science ®Google Scholar
• Itoda I, Yasunami T, Kikuchi K, Yamaura H, Totsuka K, Yoshinaga K, et al.. [Severe falciparum malaria with prolonged hemolytic anemia after successful treatment with intravenous artesunate]. Kansenshogaku Zasshi. 2002;76(8):600–3. Japanese.
   Google Scholar